These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25544843)

  • 1. Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen?
    Wilson A; Delport J; Ponich T
    Int J Microbiol; 2014; 2014():371631. PubMed ID: 25544843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients.
    Tantivitayakul P; Lapirattanakul J; Kaypetch R; Muadcheingka T
    J Glob Antimicrob Resist; 2019 Jun; 17():221-226. PubMed ID: 30658200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
    Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
    Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida esophagitis: species distribution and risk factors for infection.
    Kliemann DA; Pasqualotto AC; Falavigna M; Giaretta T; Severo LC
    Rev Inst Med Trop Sao Paulo; 2008; 50(5):261-3. PubMed ID: 18949340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Efflux Pumps and Fatty Acid Activator One Genes in Azole Resistant Candida Glabrata Isolated From Immunocompromised Patients.
    Farahyar S; Zaini F; Kordbacheh P; Rezaie S; Falahati M; Safara M; Raoofian R; Hatami K; Mohebbi M; Heidari M
    Acta Med Iran; 2016 Jul; 54(7):458-64. PubMed ID: 27424018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis.
    Miranda-Cadena K; Marcos-Arias C; Mateo E; Aguirre JM; Quindós G; Eraso E
    Arch Oral Biol; 2018 Nov; 95():100-107. PubMed ID: 30096698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.
    Vermitsky JP; Earhart KD; Smith WL; Homayouni R; Edlind TD; Rogers PD
    Mol Microbiol; 2006 Aug; 61(3):704-22. PubMed ID: 16803598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluconazole Resistant Candida Oesophagitis in Immunocompetent Patients: Is Empirical Therapy Justifiable?
    Kakati B; Kotwal A; Biswas D; Sahu S
    J Clin Diagn Res; 2015 Dec; 9(12):DC16-8. PubMed ID: 26816890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata.
    Sanglard D; Ischer F; Bille J
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1174-83. PubMed ID: 11257032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between respiration deficiency and azole resistance in clinical Candida glabrata.
    Peng Y; Dong D; Jiang C; Yu B; Wang X; Ji Y
    FEMS Yeast Res; 2012 Sep; 12(6):719-27. PubMed ID: 22713096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of azole resistance in clinical isolates of
    Yao D; Chen J; Chen W; Li Z; Hu X
    Infect Drug Resist; 2019; 12():771-781. PubMed ID: 31118695
    [No Abstract]   [Full Text] [Related]  

  • 17. Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species.
    Nagayoshi Y; Miyazaki T; Shimamura S; Nakayama H; Minematsu A; Yamauchi S; Takazono T; Nakamura S; Yanagihara K; Kohno S; Mukae H; Izumikawa K
    PLoS One; 2017; 12(7):e0180990. PubMed ID: 28700656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing.
    Spettel K; Barousch W; Makristathis A; Zeller I; Nehr M; Selitsch B; Lackner M; Rath PM; Steinmann J; Willinger B
    PLoS One; 2019; 14(1):e0210397. PubMed ID: 30629653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong
    Schell WA; Jones AM; Garvey EP; Hoekstra WJ; Schotzinger RJ; Alexander BD
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
    Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
    Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.